ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap

Hans Joachim Anders; Brad Rovin; David Jayne; Paul Brunetta; Rosanna Coppo; Anne Davidson; Satish Kumar Devarapu; Dick de Zeeuw; Jeremy Duffield; Dirk Eulberg; Alberto Fierro; Jürgen Floege; Steffen Frese; Loïc Guillevin; Stephen Holdsworth; Jeremy Hughes; Ralph Kettritz; Malte Kluger; Christian Krebs; Larissa Lapteva; Adeera Levin; Jinhua Li; Liz Lightstone; Matthias Mack; Ladan Mansouri; Stephen McAdoo; Eoin McKinney; Ulf Panzer; Samir Parikh; Charles Pusey; Chaim Putterman; Ton Rabelink; Andreas Radbruch; Andrew Rees; Mary Reilly; Marlies Reinders; Giuseppe Remuzzi; Piero Ruggenenti; Steven Sacks; Thomas J. Schall; Catherine Meyer-Schwesinger; Kumar Sharma; Yusuke Suzuki; Nicola M. Tomas; Ming Hui Zhao

doi:10.1016/j.ekir.2016.06.009

ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap

Hans Joachim Anders, Brad Rovin, David Jayne, Paul Brunetta, Rosanna Coppo, Anne Davidson, Satish Kumar Devarapu, Dick de Zeeuw, Jeremy Duffield, Dirk Eulberg, Alberto Fierro, Jürgen Floege, Steffen Frese, Loïc Guillevin, Stephen Holdsworth, Jeremy Hughes, Ralph Kettritz, Malte Kluger, Christian Krebs, Larissa LaptevaAdeera Levin, Jinhua Li, Liz Lightstone, Matthias Mack, Ladan Mansouri, Stephen McAdoo, Eoin McKinney, Ulf Panzer, Samir Parikh, Charles Pusey, Chaim Putterman, Ton Rabelink, Andreas Radbruch, Andrew Rees, Mary Reilly, Marlies Reinders, Giuseppe Remuzzi, Piero Ruggenenti, Steven Sacks, Thomas J. Schall, Catherine Meyer-Schwesinger, Kumar Sharma, Yusuke Suzuki, Nicola M. Tomas, Ming Hui Zhao

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

To date, the treatment of immune-mediated kidney diseases has only marginally benefited from highly specific biological drugs that have demonstrated remarkable effects in many other diseases. What accounts for this disparity? In April 2016, the International Society of Nephrology held a Nexus meeting on Translational Immunology in Nephrology in Berlin, Germany, to identify and discuss hurdles that block the translational flow of target identification, and preclinical and clinical target validation in the domain of immune-mediated kidney disease. A broad panel of experts including basic scientists, translational researchers, clinical trialists, pharmaceutical industry drug developers, and representatives of the American and European regulatory authorities made recommendations on how to overcome such hurdles at all levels of the translational research process. The results of these discussions are presented here, which may serve as a roadmap for how to optimize the process of developing more innovative and effective drugs for patients with immune-mediated kidney diseases.

Original language	English
Pages (from-to)	327-339
Number of pages	13
Journal	Kidney International Reports
Volume	1
Issue number	4
DOIs	https://doi.org/10.1016/j.ekir.2016.06.009
State	Published - 2016
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2016 International Society of Nephrology

Funding

We thank the International Society of Nephrology for hosting the Nexus meeting and the industry sponsors for their unrestricted educational support. The study was supported by the European Union's Horizon 2020 research and innovation program under grant agreement No. 668036 (RELENT). This report was further supported by the EU 7FP project REDDSTAR (No. 305736) and the HORIZON2020 project NEPHSTROM (No. 634086). The views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out. Alberto Fierro, Chile, was supported by “Fondecyt regular 1120731.”

Funders	Funder number
HORIZON2020 project NEPHSTROM
Seventh Framework Programme	668036, 305736, 634086
Fondo Nacional de Desarrollo Científico y Tecnológico	1120731
Horizon 2020

Keywords

autoimmunity
inflammation
lupus
rejection
stem cells
vasculitis

Access to Document

10.1016/j.ekir.2016.06.009

Cite this

Anders, H. J., Rovin, B., Jayne, D., Brunetta, P., Coppo, R., Davidson, A., Devarapu, S. K., de Zeeuw, D., Duffield, J., Eulberg, D., Fierro, A., Floege, J., Frese, S., Guillevin, L., Holdsworth, S., Hughes, J., Kettritz, R., Kluger, M., Krebs, C., ... Zhao, M. H. (2016). ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap. Kidney International Reports, 1(4), 327-339. https://doi.org/10.1016/j.ekir.2016.06.009

@article{a358510d1d774f0194be3a544fa24adb,

title = "ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap",

abstract = "To date, the treatment of immune-mediated kidney diseases has only marginally benefited from highly specific biological drugs that have demonstrated remarkable effects in many other diseases. What accounts for this disparity? In April 2016, the International Society of Nephrology held a Nexus meeting on Translational Immunology in Nephrology in Berlin, Germany, to identify and discuss hurdles that block the translational flow of target identification, and preclinical and clinical target validation in the domain of immune-mediated kidney disease. A broad panel of experts including basic scientists, translational researchers, clinical trialists, pharmaceutical industry drug developers, and representatives of the American and European regulatory authorities made recommendations on how to overcome such hurdles at all levels of the translational research process. The results of these discussions are presented here, which may serve as a roadmap for how to optimize the process of developing more innovative and effective drugs for patients with immune-mediated kidney diseases.",

keywords = "autoimmunity, inflammation, lupus, rejection, stem cells, vasculitis",

author = "Anders, {Hans Joachim} and Brad Rovin and David Jayne and Paul Brunetta and Rosanna Coppo and Anne Davidson and Devarapu, {Satish Kumar} and {de Zeeuw}, Dick and Jeremy Duffield and Dirk Eulberg and Alberto Fierro and J{\"u}rgen Floege and Steffen Frese and Lo{\"i}c Guillevin and Stephen Holdsworth and Jeremy Hughes and Ralph Kettritz and Malte Kluger and Christian Krebs and Larissa Lapteva and Adeera Levin and Jinhua Li and Liz Lightstone and Matthias Mack and Ladan Mansouri and Stephen McAdoo and Eoin McKinney and Ulf Panzer and Samir Parikh and Charles Pusey and Chaim Putterman and Ton Rabelink and Andreas Radbruch and Andrew Rees and Mary Reilly and Marlies Reinders and Giuseppe Remuzzi and Piero Ruggenenti and Steven Sacks and Schall, {Thomas J.} and Catherine Meyer-Schwesinger and Kumar Sharma and Yusuke Suzuki and Tomas, {Nicola M.} and Zhao, {Ming Hui}",

note = "Publisher Copyright: {\textcopyright} 2016 International Society of Nephrology",

year = "2016",

doi = "10.1016/j.ekir.2016.06.009",

language = "אנגלית",

volume = "1",

pages = "327--339",

journal = "Kidney International Reports",

issn = "2468-0249",

publisher = "Elsevier Inc.",

number = "4",

}

Anders, HJ, Rovin, B, Jayne, D, Brunetta, P, Coppo, R, Davidson, A, Devarapu, SK, de Zeeuw, D, Duffield, J, Eulberg, D, Fierro, A, Floege, J, Frese, S, Guillevin, L, Holdsworth, S, Hughes, J, Kettritz, R, Kluger, M, Krebs, C, Lapteva, L, Levin, A, Li, J, Lightstone, L, Mack, M, Mansouri, L, McAdoo, S, McKinney, E, Panzer, U, Parikh, S, Pusey, C, Putterman, C, Rabelink, T, Radbruch, A, Rees, A, Reilly, M, Reinders, M, Remuzzi, G, Ruggenenti, P, Sacks, S, Schall, TJ, Meyer-Schwesinger, C, Sharma, K, Suzuki, Y, Tomas, NM & Zhao, MH 2016, 'ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap', Kidney International Reports, vol. 1, no. 4, pp. 327-339. https://doi.org/10.1016/j.ekir.2016.06.009

TY - JOUR

T1 - ISN Nexus 2016 Symposia

T2 - Translational Immunology in Kidney Disease—The Berlin Roadmap

AU - Anders, Hans Joachim

AU - Rovin, Brad

AU - Jayne, David

AU - Brunetta, Paul

AU - Coppo, Rosanna

AU - Davidson, Anne

AU - Devarapu, Satish Kumar

AU - de Zeeuw, Dick

AU - Duffield, Jeremy

AU - Eulberg, Dirk

AU - Fierro, Alberto

AU - Floege, Jürgen

AU - Frese, Steffen

AU - Guillevin, Loïc

AU - Holdsworth, Stephen

AU - Hughes, Jeremy

AU - Kettritz, Ralph

AU - Kluger, Malte

AU - Krebs, Christian

AU - Lapteva, Larissa

AU - Levin, Adeera

AU - Li, Jinhua

AU - Lightstone, Liz

AU - Mack, Matthias

AU - Mansouri, Ladan

AU - McAdoo, Stephen

AU - McKinney, Eoin

AU - Panzer, Ulf

AU - Parikh, Samir

AU - Pusey, Charles

AU - Putterman, Chaim

AU - Rabelink, Ton

AU - Radbruch, Andreas

AU - Rees, Andrew

AU - Reilly, Mary

AU - Reinders, Marlies

AU - Remuzzi, Giuseppe

AU - Ruggenenti, Piero

AU - Sacks, Steven

AU - Schall, Thomas J.

AU - Meyer-Schwesinger, Catherine

AU - Sharma, Kumar

AU - Suzuki, Yusuke

AU - Tomas, Nicola M.

AU - Zhao, Ming Hui

PY - 2016

Y1 - 2016

N2 - To date, the treatment of immune-mediated kidney diseases has only marginally benefited from highly specific biological drugs that have demonstrated remarkable effects in many other diseases. What accounts for this disparity? In April 2016, the International Society of Nephrology held a Nexus meeting on Translational Immunology in Nephrology in Berlin, Germany, to identify and discuss hurdles that block the translational flow of target identification, and preclinical and clinical target validation in the domain of immune-mediated kidney disease. A broad panel of experts including basic scientists, translational researchers, clinical trialists, pharmaceutical industry drug developers, and representatives of the American and European regulatory authorities made recommendations on how to overcome such hurdles at all levels of the translational research process. The results of these discussions are presented here, which may serve as a roadmap for how to optimize the process of developing more innovative and effective drugs for patients with immune-mediated kidney diseases.

AB - To date, the treatment of immune-mediated kidney diseases has only marginally benefited from highly specific biological drugs that have demonstrated remarkable effects in many other diseases. What accounts for this disparity? In April 2016, the International Society of Nephrology held a Nexus meeting on Translational Immunology in Nephrology in Berlin, Germany, to identify and discuss hurdles that block the translational flow of target identification, and preclinical and clinical target validation in the domain of immune-mediated kidney disease. A broad panel of experts including basic scientists, translational researchers, clinical trialists, pharmaceutical industry drug developers, and representatives of the American and European regulatory authorities made recommendations on how to overcome such hurdles at all levels of the translational research process. The results of these discussions are presented here, which may serve as a roadmap for how to optimize the process of developing more innovative and effective drugs for patients with immune-mediated kidney diseases.

KW - autoimmunity

KW - inflammation

KW - lupus

KW - rejection

KW - stem cells

KW - vasculitis

UR - http://www.scopus.com/inward/record.url?scp=84995563999&partnerID=8YFLogxK

U2 - 10.1016/j.ekir.2016.06.009

DO - 10.1016/j.ekir.2016.06.009

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:84995563999

SN - 2468-0249

VL - 1

SP - 327

EP - 339

JO - Kidney International Reports

JF - Kidney International Reports

IS - 4

ER -

ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap

Abstract

Bibliographical note

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this